NCT04347473 ILUMYA in Combination With HALOG Ointment 0.1% for Plaque Psoriasis.
| NCT ID | NCT04347473 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | Psoriasis Treatment Center of Central New Jersey |
| Condition | Psoriasis |
| Study Type | INTERVENTIONAL |
| Enrollment | 25 participants |
| Start Date | 2020-04-06 |
| Primary Completion | 2020-12-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 25 participants in total. It began in 2020-04-06 with a primary completion date of 2020-12-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Patient with moderate-to-severe plaque psoriasis will receive Ilumya with or without Halog ointment.
Eligibility Criteria
Inclusion Criteria: 1. Male or female adult ≥ 18 years of age; 2. Diagnosis of moderate-to-severe chronic plaque-type psoriasis as defined by * BSA 10% * PGA ≥3 * PASI ≥12 3. Must be a candidate for phototherapy and/or systemic therapy 4. Females of childbearing potential (FCBP) must have a negative serum pregnancy test at Screening and negative urine pregnancy test at Baseline. FCBP who engage in activity in which conception is possible must use one of the approved contraceptive options: hormonal contraception; intrauterine device (IUD); tubal ligation; or partner's vasectomy; Male or female condom diaphragm with spermicide, cervical cap with spermicide, or contraceptive sponge with spermicide. Exclusion Criteria: 1. Non-plaque forms of psoriasis 2. Women of childbearing potential who are pregnant, intend to become pregnant, or are lactating 3. Presence of significant uncontrolled medical condition that in the opinion of the investigator would affect patient safety during the trial. 4. Active or untreated latent tuberculosis (TB)
Contact & Investigator
Frequently Asked Questions
Who can join the NCT04347473 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Psoriasis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT04347473 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT04347473 currently recruiting?
Yes, NCT04347473 is actively recruiting participants. Contact the research team at dreamacres1@aol.com for enrollment information.
Where is the NCT04347473 trial being conducted?
This trial is being conducted at East Windsor, United States.
Who is sponsoring the NCT04347473 clinical trial?
NCT04347473 is sponsored by Psoriasis Treatment Center of Central New Jersey. The trial plans to enroll 25 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.